Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13. 2 months compared with 6. 7 months for chemotherapy recipients, studies showed.

Source: [CBS News](https://www.cbsnews.com/news/fda-approves-pancreatic-cancer-drug-daraxonrasib-could-extend-patients-lives/)

Sponsored